BrightSpring: Specialty Pharmacy Growth, Structural Tailwinds, and Upside to Long-Term EBITDA Targets Support Buy Rating

TD Cowen analyst Charles Rhyee has maintained their bullish stance on BTSG stock, giving a Buy rating yesterday.

Charles Rhyee has given his Buy rating due to a combination of factors tied to BrightSpring’s long‑term growth outlook and conservative near‑term guidance. He views management’s 15–20% organic EBITDA growth goal for 2026–2028 as achievable with upside, supported by ongoing gains from generics and biosimilars, continued long‑duration drug wins, and structural trends that should persist well past 2028.

He also highlights management’s emphasis on specialty pharmacy, where a large late‑stage oncology pipeline and expected new product launches over the next several years provide significant volume and revenue visibility. In his view, BrightSpring’s strong performance metrics, advantages in increasingly concentrated limited‑distribution drug networks, and investments in rare/orphan and infusion capabilities support both sustained growth and potential valuation multiple expansion.

According to TipRanks, Rhyee is a 3-star analyst with an average return of 1.8% and a 47.76% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Cardinal Health, McKesson, and BrightSpring Health Services, Inc..

In another report released yesterday, William Blair also reiterated a Buy rating on the stock with a $42.10 price target.